Drug Safety

, Volume 9, Issue 6, pp 429–436

Adverse Effects of Antipsychotic Drugs

  • Anil K. Malhotra
  • Robert E. Litman
  • David Pickar
Review Article Drug Experience


Since the introduction of chlorpromazine in the 1950s, neuroleptic medications have been the mainstay of treatment of schizophrenia and other psychotic disorders. These medications do not always lead to complete remission of symptoms but they have allowed many patients to lead more productive and satisfying lives away from the restrictions of chronic hospitalisation. However, neuroleptics are associated with a number of adverse effects that can compromise their effectiveness. Extrapyramidal adverse effects include acute dystonic reactions, neuroleptic-induced Parkinsonism and akathisia. They can often be treated with neuroleptic dose reduction, addition of anticholinergic or β-blocking agents, or medication change. Later-onset movement disorders such as tardive dyskinesia or dystonia require careful evaluation and may be treated with dose reduction or change of neuroleptic to an atypical agent. Potentially fatal reactions such as agranulocytosis and neuroleptic malignant syndrome can rarely occur and often require significant medical intervention. Clozapine offers some advantages over ‘typical’ neuroleptics but has a unique adverse effect profile which includes agranulocytosis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adler LA, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. Journal of Clinical Psychopharmacology 5: 164–166, 1985PubMedCrossRefGoogle Scholar
  2. Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology 97: 1–11, 1989PubMedCrossRefGoogle Scholar
  3. Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry 52: 102–104, 1991PubMedGoogle Scholar
  4. Ayd FJ. A survey of drug induced extrapyramidal reactions. Journal of the American Medical Association 175: 1054–1060, 1961PubMedCrossRefGoogle Scholar
  5. Barnes TRE, Braude WM. Tardive dyskinesia: a 3 year follow-up study. Psychological Medicine 13: 71–81, 1983PubMedCrossRefGoogle Scholar
  6. Bernstein J. Antipsychotic drugs. In Bernstein (Ed.) Drug therapy in psychiatry, 2nd ed., pp. 79–122, PSG Publishing Co. Inc., Littleton, 1988Google Scholar
  7. Borison RL. Amantadine in the management of extrapyramidal side effects. Clinical Neuropharmacology 6(Suppl. 1): 57–63, 1983CrossRefGoogle Scholar
  8. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. Journal of Clinical Psychopharmacology 7: 164–166, 1987PubMedGoogle Scholar
  9. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia. British Journal of Psychiatry 143: 139–150, 1983PubMedCrossRefGoogle Scholar
  10. Casey DE. Tardive dyskinesia. In Meltzer (Ed.) Psychopharmacology the third generation of progress, pp. 1411–1419, Raven Press, New York, 1987Google Scholar
  11. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: S47–S53, 1989PubMedCrossRefGoogle Scholar
  12. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 4: 109–120, 1991PubMedCrossRefGoogle Scholar
  13. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JMJ, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacology Bulletin 28: 81–86, 1992PubMedGoogle Scholar
  14. Daouda P, Delacour JL. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 2: 217, 1982CrossRefGoogle Scholar
  15. DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52: 105–107, 1991PubMedGoogle Scholar
  16. Dickey W. The neuroleptic malignant syndrome. Progress in Neurobiology 36: 425–436, 1991PubMedCrossRefGoogle Scholar
  17. Ducomb L, Baldessarini RJ. Timing and risk of bone marrow depression by psychotropic drugs. American Journal of Psychiatry 134: 1294–1295, 1977PubMedGoogle Scholar
  18. Fink M, Irwin P, Weinhold P. EEG profile studies of clozapine in volunteers and psychiatric patients. Pharmakopsychiatrie 12: 184–190,1979CrossRefGoogle Scholar
  19. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scandinavica 77: 369–378, 1988PubMedCrossRefGoogle Scholar
  20. Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, et al. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Annals of Neurology 14: 89–90, 1983PubMedCrossRefGoogle Scholar
  21. Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Seminars in Neurology 11: 228–235, 1991PubMedCrossRefGoogle Scholar
  22. Grohmann R, Ruther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 99: S101–S104, 1989PubMedCrossRefGoogle Scholar
  23. Guze BH, Baxter LR. Current concepts: neuroleptic malignant syndrome. New England Journal of Medicine 313: 163–166, 1985PubMedCrossRefGoogle Scholar
  24. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: two decades of experience. Archives of General Psychiatry 39: 803–816, 1982PubMedCrossRefGoogle Scholar
  25. Kane JM, Honigfeld G, Singer J, Meitzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789–796, 1988PubMedCrossRefGoogle Scholar
  26. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, et al. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacology Bulletin 20a: 387–389, 1984Google Scholar
  27. Kaufman DM. Clinical neurology for psychiatrists, 2nd ed., Grune and Stratton Inc., Orlando, 1985Google Scholar
  28. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Archives of General Psychiatry 46: 914–918, 1989PubMedCrossRefGoogle Scholar
  29. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 40: 1113–1117, 1983PubMedCrossRefGoogle Scholar
  30. Koukkou M, Angst J, Zimmer D. Paroxysmal EEG activity and psychopathology during the treatment with clozapine. Pharmakopsychiatrie 12: 173–183, 1979CrossRefGoogle Scholar
  31. Krupp P and Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99: S118–S121, 1989PubMedCrossRefGoogle Scholar
  32. Levinson DF. Pharmacologic treatment of schizophrenia. Clinical Therapeutics 13: 326–352, 1991PubMedGoogle Scholar
  33. Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry 47: 761–768, 1990PubMedCrossRefGoogle Scholar
  34. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly 63: 51–70,1992PubMedCrossRefGoogle Scholar
  35. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacology Bulletin 25: 57–62, 1989PubMedGoogle Scholar
  36. Lipinski JF, Zubenko GS, Barriera P, Cohen BM. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 2: 685–686,1983PubMedCrossRefGoogle Scholar
  37. Lipinski JF, Zubenko GS, Cohen BM, Barreira PJ. Propranolol in the treatment of neuroleptic-induced akathisia. American Journal of Psychiatry 141: 412–415, 1984PubMedGoogle Scholar
  38. McCarron MM, Boettger ML, Peck JJ. A case of neuroleptic malignant syndrome successfully treated with amantadine. Journal of Clinical Psychiatry 43: 381–382, 1982PubMedGoogle Scholar
  39. McEvoy JP, Schooler NR, Wilson WM. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 27: 97–101, 1991PubMedGoogle Scholar
  40. Miller DM, Sharafuddin MJA, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52: 99–101, 1991PubMedGoogle Scholar
  41. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: S73–S76, 1989PubMedCrossRefGoogle Scholar
  42. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry 137:1518–1522, 1980PubMedGoogle Scholar
  43. Pickar D. Pharmacotherapeutic approaches to schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989Google Scholar
  44. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Archives of General Psychiatry 49: 345–353, 1992PubMedCrossRefGoogle Scholar
  45. Pickar D, Owen RR, Litman RE. New developments in the pharmacotherapy of schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1991, Bethesda, Maryland, November 8–9, 1991Google Scholar
  46. Rifkin A, Siris S. Drug treatment of acute schizophrenia. In Meitzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1095–1101, Raven Press, New York, 1987Google Scholar
  47. Rosebush PI, Stewart TD. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 146: 717–725, 1989PubMedGoogle Scholar
  48. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry 50: 295–298, 1989PubMedGoogle Scholar
  49. Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Archives of Internal Medicine 149: 1927–1931, 1989PubMedCrossRefGoogle Scholar
  50. Sachdev P. Clinical characteristics of 15 patients with tardive dystonia. American Journal of Psychiatry 150: 498–500, 1993PubMedGoogle Scholar
  51. Safferman AZ, Lieberman JA, Alvir NMJ, Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet 339: 1296–1297, 1992PubMedCrossRefGoogle Scholar
  52. Shalev A, Hermesh H, Munitz H. The role of external heat load in triggering the neuroleptic malignant syndrome. American Journal of Psychiatry 145: 110–111, 1988PubMedGoogle Scholar
  53. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavia 73: 337–347,1986CrossRefGoogle Scholar
  54. Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. Acute dystonia during fixed dose neuroleptic treatment. Journal of Clinical Psychopharmacology 10: 389–396, 1990PubMedCrossRefGoogle Scholar
  55. Slack T, Stoudemire A. Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome. General Hospital Psychiatry 11: 365–367, 1989PubMedCrossRefGoogle Scholar
  56. Snyder SH. Receptors, neurotransmitters and drug responses. New England Journal of Medicine 300: 465–472, 1979PubMedCrossRefGoogle Scholar
  57. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry 31: 67–72, 1974PubMedCrossRefGoogle Scholar
  58. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 41: 1036–1039, 1984PubMedCrossRefGoogle Scholar
  59. Wyatt RJ. Untoward effects of neuroleptic treatment. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Anil K. Malhotra
    • 1
  • Robert E. Litman
    • 1
  • David Pickar
    • 1
  1. 1.Experimental Therapeutics BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations